Logo image of CSII

CARDIOVASCULAR SYSTEMS INC (CSII) Stock Fundamental Analysis

NASDAQ:CSII - Nasdaq - US1416191062 - Common Stock - Currency: USD

20  +0.03 (+0.15%)

After market: 20 0 (0%)

Fundamental Rating

3

Overall CSII gets a fundamental rating of 3 out of 10. We evaluated CSII against 189 industry peers in the Health Care Equipment & Supplies industry. While CSII seems to be doing ok healthwise, there are quite some concerns on its profitability. CSII is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CSII had negative earnings in the past year.
In the past year CSII has reported a negative cash flow from operations.
CSII had negative earnings in 4 of the past 5 years.
In multiple years CSII reported negative operating cash flow during the last 5 years.
CSII Yearly Net Income VS EBIT VS OCF VS FCFCSII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M

1.2 Ratios

CSII has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSII Yearly ROA, ROE, ROICCSII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -10 -20 -30 -40 -50

1.3 Margins

CSII has a Gross Margin of 72.39%. This is amongst the best in the industry. CSII outperforms 82.46% of its industry peers.
In the last couple of years the Gross Margin of CSII has declined.
The Profit Margin and Operating Margin are not available for CSII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-1.96%
CSII Yearly Profit, Operating, Gross MarginsCSII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

CSII does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSII has more shares outstanding than it did 1 year ago.
CSII has a worse debt/assets ratio than last year.
CSII Yearly Shares OutstandingCSII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
CSII Yearly Total Debt VS Total AssetsCSII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

CSII has an Altman-Z score of 6.06. This indicates that CSII is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.06, CSII belongs to the best of the industry, outperforming 80.57% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that CSII is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.08, CSII perfoms like the industry average, outperforming 58.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 6.06
ROIC/WACCN/A
WACC9.65%
CSII Yearly LT Debt VS Equity VS FCFCSII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.04 indicates that CSII has no problem at all paying its short term obligations.
CSII has a Current ratio of 6.04. This is in the better half of the industry: CSII outperforms 72.99% of its industry peers.
CSII has a Quick Ratio of 4.92. This indicates that CSII is financially healthy and has no problem in meeting its short term obligations.
CSII's Quick ratio of 4.92 is fine compared to the rest of the industry. CSII outperforms 72.04% of its industry peers.
Industry RankSector Rank
Current Ratio 6.04
Quick Ratio 4.92
CSII Yearly Current Assets VS Current LiabilitesCSII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

CSII shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.97%.
CSII shows a decrease in Revenue. In the last year, the revenue decreased by -4.73%.
The Revenue has been growing slightly by 2.89% on average over the past years.
EPS 1Y (TTM)-46.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)-4.73%
Revenue growth 3Y-1.61%
Revenue growth 5Y2.89%
Sales Q2Q%3.92%

3.2 Future

CSII is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.08% yearly.
The Revenue is expected to grow by 10.69% on average over the next years. This is quite good.
EPS Next Y28.21%
EPS Next 2Y21.47%
EPS Next 3Y19.08%
EPS Next 5YN/A
Revenue Next Year8.64%
Revenue Next 2Y9.57%
Revenue Next 3Y10.69%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSII Yearly Revenue VS EstimatesCSII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
CSII Yearly EPS VS EstimatesCSII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CSII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CSII. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSII Price Earnings VS Forward Price EarningsCSII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSII Per share dataCSII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as CSII's earnings are expected to grow with 19.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.47%
EPS Next 3Y19.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CSII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOVASCULAR SYSTEMS INC

NASDAQ:CSII (4/27/2023, 8:22:19 PM)

After market: 20 0 (0%)

20

+0.03 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-03 2023-05-03/amc
Earnings (Next)07-31 2023-07-31/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners5.24%
Ins Owner Change0%
Market Cap839.18M
Analysts48.33
Price Target17.75 (-11.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.68%
Min EPS beat(2)-28.27%
Max EPS beat(2)-15.09%
EPS beat(4)1
Avg EPS beat(4)-10.65%
Min EPS beat(4)-28.27%
Max EPS beat(4)13.04%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)-1.09%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-4.49%
Max Revenue beat(4)-1.09%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.9%
EPS NY rev (1m)0%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.5
P/FCF N/A
P/OCF N/A
P/B 3.51
P/tB 3.74
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS5.72
BVpS5.71
TBVpS5.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.39%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-1.96%
F-Score2
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.93%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.04
Quick Ratio 4.92
Altman-Z 6.06
F-Score2
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)91.15%
Cap/Depr(5y)90.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y28.21%
EPS Next 2Y21.47%
EPS Next 3Y19.08%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.73%
Revenue growth 3Y-1.61%
Revenue growth 5Y2.89%
Sales Q2Q%3.92%
Revenue Next Year8.64%
Revenue Next 2Y9.57%
Revenue Next 3Y10.69%
Revenue Next 5YN/A
EBIT growth 1Y-41.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.76%
EBIT Next 3Y32.49%
EBIT Next 5YN/A
FCF growth 1Y-111.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-154.42%
OCF growth 3YN/A
OCF growth 5YN/A